Estimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Schmidt, Daniel ^a   Kollan, Christian ^a   Fätkenheuer, Gerd ^b   Schülter, Eugen ^b   Stellbrink, Hans Jürgen ^c   Noah, Christian ^d   Jensen, Björn Erik Ole ^e   Stoll, Matthias ^f   Bogner, Johannes R ^g   Eberle, Josef ^h   Meixenberger, Karolin ^a   Kücherer, Claudia ^a   Hamouda, Osamah ^a   Bartmeyer, Barbara ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Infektionsmedizinisches Centrum Hamburg   (Germany)

^d Laboratory Lademannbogen ^*  (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG SURVEILLANCE PROGRAM; FEMALE; GENOTYPE; GERMANY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; PROSPECTIVE STUDY; TREND STUDY; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTICENTER STUDY; MUTATION; RISK FACTOR; TRANSMISSION; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; GERMANY; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; RISK FACTORS; VIRAL LOAD;

EID: 84920914620     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104474     Document Type: Article

References (26)

1. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med 338: 853-860. (Pubitemid 28135961)
2. Jones J, Taylor B, Wilkin TJ, Hammer SM (2007) Advances in antiretroviral therapy. Top HIV Med 15: 48-82.
3. Kauf TL, Davis KL, Earnshaw SR, Davis EA (2012) Spillover adherence effects of fixed-dose combination HIV therapy. Patient Prefer Adherence 6: 155.
4. Llibre JM, Arribas JR, Domingo P, Gatell JM, Lozano F, et al. (2011) Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. Aids 25: 1683-1690.
5. Brenner BG, Roger M, Moisi DD, Oliveira M, Hardy I, et al. (2008) Transmission networks of drug resistance acquired in primary/early stage HIV infection. Aids 22: 2509-2515.
6. de Mendoza C, Garrido C, Corral A, Ramirez-Olivencia G, Jimenez-Nacher I, et al. (2007) Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses 23: 879-885. (Pubitemid 47267494)
7. BUB-Richtlinien/Anlage A (2004) Genotypische Resistenztestung. Bundesanzeiger Nr. 57 (S. 5679).
8. Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, et al. (2010) Prevalence of Transmitted Drug Resistance and Impact of Transmitted Resistance on Treatment Success in the German HIV-1 Seroconverter Cohort. PLoS ONE 5: e12718.
9. Oette M, Kaiser R, Daumer M, Fatkenheuer G, Rockstroh JK, et al. (2007) Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005. Dtsch Med Wochenschr 132: 977-982. (Pubitemid 46740267)
10. Descamps D, Chaix ML, Andre P, Brodard V, Cottalorda J, et al. (2005) French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 38: 545-552. (Pubitemid 40524476)
11. Costagliola D, Descamps D, Assoumou L, Morand-Joubert L, Marcelin AG, et al. (2007) Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr 46: 12-18. (Pubitemid 47507429)
12. zu Knyphausen F, Scheufele R, Kücherer C, Jansen K, Somogyi S, et al. (2014) First Line Treatment Response in Patients with Transmitted HIV Drug Resistance and Well Defined Time Point of HIV Infection: Updated Results from the German HIV-1 Seroconverter Study. PLoS ONE 9(5): e95956.
13. Bätzing-Feigenbaum J, Kollan C, Kühne A, Matysiak-Klose D, Gunsenheimer-Bartmeyer B, et al. (2011) Cohort Profile: The German ClinSurv HIV project. A multicentre open clinical cohort as supplement of national HIV surveillance. HIV Medicine 12: 269-278.
14. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4: e4724.
15. Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, et al. (2011) 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156-164.
16. De Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21: 3797-3800. (Pubitemid 41535530)
17. Bezemer D, Jurriaans S, Prins M, van der Hoek L, Prins JM, et al. (2004) Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. Aids.18: 1571-1577. (Pubitemid 39037481)
18. UK Collaborative Group on HIV Drug Resistance (2007) Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. Aids 21: 1035-1039.
19. Sagir A, Oette M, Kaiser R, Daumer M, Fatkenheuer G, et al. (2007) Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 60: 843-848. (Pubitemid 47434265)
20. Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, et al. (2004) Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 72: 162-165. (Pubitemid 37484758)
21. Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, et al. (2012) Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ (Clinical Research ed.) 345: e5253.
22. Betancor G, Garriga C, Puertas MC, Nevot M, Anta L, et al. (2012) Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. Retrovirology 9: 68.
23. De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, et al. (2013) Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis207: 1216-20.
24. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, et al. (2001) Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. New Engl J Med 344: 472-480. (Pubitemid 32164898)
25. Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, et al. (2008) Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 197: 1145-1155. (Pubitemid 351590050)
26. Tejerina F, de Quirós JCLB (2011) Protease Inhibitors as Preferred Initial Regimen for Antiretroviral-Naive HIV Patients. AIDS Rev 13: 227-233.